Emily R Atkins, Alexander Chye, Thomas Lung, Janis M Nolde, Laurent Billot, Michael Burke, John Chalmers, Gemma A Figtree, Peter Hay, Graham S Hillis, Shirley Jansen, Simone Marschner, Bruce Neal, Mark R Nelson, Christopher M Reid, Tim Usherwood, Markus Schlaich, Clara K Chow, Anthony Rodgers
OBJECTIVE: To determine the cost-effectiveness and cost-utility of a quadpill containing irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg and bisoprolol 2.5 mg in comparison with irbesartan 150 mg for people with hypertension who are either untreated or receiving monotherapy. METHODS: We conducted a within-trial and modelled economic evaluation of the Quadruple UltrA-low-dose tReaTment for hypErTension trial. The analysis was preplanned, and medications and health service use captured during the trial...
October 26, 2023: Heart